New stability testing rules for generics

Home/Policies & Legislation | Posted 28/10/2011 post-comment0 Post your comment

Both EMA and FDA are increasing their requirements for stability testing, especially for generic drugs. These changes could significantly increase the length of time required to gain regulatory approval and increase costs for generics manufacturers to get their drugs onto the market.

picture 97

EMA issued new draft guidelines in August 2011 on stability testing required to support a variation to a marketing authorisation. Under the new rules, additional data must be submitted to accompany major, type II variations, such as a change in batch size or switching suppliers. The draft document is posted on the EMA website.

FDA announced on 4 October 2011 that it will soon require generic drugmakers to submit 12 months of product stability data with abbreviated new drug applications (ANDAs)—four times as long as currently mandated. At the moment certain new drug applications must have 12 months real-time and six months accelerated stability testing on three batches at the time of filing. Until now, ANDAs had to have just three months of accelerated stability data at filing to get two years of shelf life—confirmed later by room temperature data.

The draft FDA proposals are at the moment open for comments. They will increase the stringency of stability test for generics manufacturers similar to what is required for original marketing authorisations. An ANDA will take nine months longer before filing and cost more to develop. So in the US additional stability requirements, generics user fees and the increased documentation will continue to put pressure on smaller generics companies.

Related articles

Still no word from FDA on generic user fees

Negotiations on generic drug user fees

Source: Camargoblog, EMA, FDAnews, Regulatory Affairs Professionals Society

comment icon Comments (0)
Post your comment
Related content
Public consultation for the modification of the biosimilars regulation
02 AA010638
Home/Policies & Legislation Posted 16/01/2024
COFEPRIS promotes regulatory cooperation in the Americas
Latin America 1638px
Home/Policies & Legislation Posted 12/12/2023
ANVISA's decision on 'Skinny labels' for generics pending
Labelling V14I26
Home/Policies & Legislation Posted 14/11/2023
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010